AL002

DRUG3 trials

Sponsors

Alector Inc.

Conditions

Alzheimer DiseaseAlzheimer's DiseaseHealthy

Phase 1

A Phase I Study for Safety and Tolerability of AL002.

CompletedNCT03635047

Alector Inc.Alzheimer Disease, Healthy

Start: 2018-11-12End: 2020-11-25Updated: 2020-12-09

Phase 2

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

CompletedNCT04592874

Alector Inc.Alzheimer Disease

Start: 2021-01-22End: 2024-09-12Updated: 2025-10-29

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

TerminatedNCT05744401

Alector Inc.Alzheimer's Disease

Start: 2023-01-04End: 2025-02-05Updated: 2026-02-25

Related Papers

The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial.

2026-03-05

Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease.

2024-10-2338 citations

Assessing preparedness for Alzheimer disease‐modifying therapies in Australasian health care systems

The Medical Journal of Australia2023-03-1916 citations

INVOKE-2 - A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL002 in Participants with Early Alzheimer’s Disease (P17-3.005)

Neurology2022-05-036 citations

INVOKE‐2: A phase 2 randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of AL002 in participants with early Alzheimer’s disease

Alzheimer s & Dementia2021-12-019 citations